Clinical Application of a Graphene Oxide-Based Surface Plasmon Resonance Biosensor to Measure First-Trimester Serum Pregnancy-Associated Plasma Protein-A/A2 Ratio to Predict Preeclampsia

References

• Steegers EA, von Dadelszen P, Duvekot JJ, et al. Pre-eclampsia. Lancet. 2010;376:631–644. doi:10.1016/S0140-6736(10)60279-6
   PubMed Web of Science ®Google Scholar
• Burton GJ, Redman CW, Roberts JM, et al. Pre-eclampsia: pathophysiology and clinical implications. BMJ. 2019;366:I2381. doi:10.1136/bmj.l2381.
   PubMedGoogle Scholar
• Rana S, Lemoine E, Granger JP, et al. Preeclampsia: pathophysiology, challenges, and perspectives. Circ Res. 2019;124:1094–1112. doi:10.1161/CIRCRESAHA.118.313276
   PubMed Web of Science ®Google Scholar
• Giudice LC, Martina NA, Crystal RA, et al. Insulin-like growth factor binding protein-1 at the maternal-fetal interface and insulin-like growth factor-I, insulin-like growth factor-II, and insulin-like growth factor binding protein-1 in the circulation of women with severe preeclampsia. Am J Obstet Gynecol. 1997;176:751–757. doi:10.1016/S0002-9378(97)70598-2
   PubMed Web of Science ®Google Scholar
• Boldt HB, Overgaard MT, Laursen LS, et al. Mutational analysis of the proteolytic domain of pregnancy-associated plasma protein-A (PAPP-A): classification as a metzincin. Biochem J. 2001;358:359–367. doi:10.1042/bj3580359
   PubMed Web of Science ®Google Scholar
• Overgaard MT, Boldt HB, Laursen LS, et al. Pregnancy-associated plasma protein-A2 (PAPP-A2), a novel insulin-like growth factor-binding protein-5 proteinase. J Biol Chem. 2001;276:21849–21853. doi:10.1074/jbc.M102191200
   PubMed Web of Science ®Google Scholar
• Poon LC, Maiz N, Valencia C, et al. First-trimester maternal serum pregnancy-associated plasma protein-A and pre-eclampsia. Ultrasound Obstet Gynecol. 2009;33:23–33. doi:10.1002/uog.6280
   PubMed Web of Science ®Google Scholar
• Hourrier S, Salomon LJ, Dreux S, et al. Screening for adverse pregnancy outcome at early gestational age. Clin Chim Acta. 2010;411:1547–1552. doi:10.1016/j.cca.2010.06.024
   PubMed Web of Science ®Google Scholar
• Crosley EJ, Durland U, Seethram K, et al. First-trimester levels of pregnancy-associated plasma protein A2 (PAPP-A2) in the maternal circulation are elevated in pregnancies that subsequently develop preeclampsia. Reprod Sci. 2014;21:754–760. doi:10.1177/1933719113512532
   PubMed Web of Science ®Google Scholar
• Neuman RI, Alblas van der Meer MM, Nieboer D, et al. PAPP-A2 and inhibin A as novel predictors for pregnancy complications in women with suspected or confirmed preeclampsia. J Am Heart Assoc. 2020;9:e018219.
   PubMed Web of Science ®Google Scholar
• Suman P, Gandhi S, Kumar P, et al. Prospects of electrochemical immunosensors for early diagnosis of preeclampsia. Am J Reprod Immunol. 2017;77. doi:10.1111/aji.12584
   PubMed Web of Science ®Google Scholar
• Li J, Liu G, Zhang W, et al. Competitive detection of pregnancy-associated plasma protein-A in serum using functional single walled carbon nanotubes/chitosan-based electrochemical immunosensor. J Electroanal Chem. 2013;708:95–100. doi:10.1016/j.jelechem.2013.09.026
   Web of Science ®Google Scholar
• Bocková M, Chadtová Song X, Gedeonová E, et al. Surface plasmon resonance biosensor for detection of pregnancy associated plasma protein A2 in clinical samples. Anal Bioanal Chem. 2016;408:7265–7269. doi:10.1007/s00216-016-9664-z
   PubMed Web of Science ®Google Scholar
• Kang YE, Seong KY, Yim SG, et al. Nanochannel-driven rapid capture of sub-nanogram level biomarkers for painless preeclampsia diagnosis. Biosens Bioelectron. 2020;163:112281. doi:10.1016/j.bios.2020.112281
   PubMed Web of Science ®Google Scholar
• Pham TTT, Tran DP, Nguyen MC, et al. A simplified point-of-care testing approach for preeclampsia blood biomarkers based on nanoscale field effect transistors. Nanoscale. 2021;13:12279–12287. doi:10.1039/D1NR02461B
   PubMed Web of Science ®Google Scholar
• Chiu NF, Tai MJ, Wu HP, et al. Development of a bioaffinity SPR immunosensor based on functionalized graphene oxide for the detection of pregnancy-associated plasma protein A2 in human plasma. Int J Nanomedicine. 2019;14:6735–6748. doi:10.2147/IJN.S213653
   PubMed Web of Science ®Google Scholar
• Fan SY, Chiu NF, Chen CP, et al. Simultaneous real-time detection of pregnancy-associated plasma protein-A and -A2 using a graphene oxide-based surface plasmon resonance biosensor. Int J Nanomedicine. 2020;15:2085–2094. doi:10.2147/IJN.S237938
   PubMed Web of Science ®Google Scholar
• Reina G, González-Domínguez JM, Criado A, et al. Promises, facts and challenges for graphene in biomedical applications. Chem Soc Rev. 2017;46:4400–4416. doi:10.1039/C7CS00363C
   PubMed Web of Science ®Google Scholar
• Hegab HM, ElMekawy A, Zou L, et al. The controversial antibacterial activity of graphene-based materials. Carbon. 2016;105:362–376. doi:10.1016/j.carbon.2016.04.046
   Web of Science ®Google Scholar
• Liu J, Cui L, Losic D. Graphene and graphene oxide as new nanocarriers for drug delivery applications. Acta Biomater. 2013;9:9243–9257.
   PubMed Web of Science ®Google Scholar
• Chung C, Kim YK, Shin D, et al. Biomedical applications of graphene and graphene oxide. Acc Chem Res. 2013;46:2211–2224. doi:10.1021/ar300159f
   PubMed Web of Science ®Google Scholar
• Velasco-Soto MA, Pérez-García SA, Alvarez-Quintana J, et al. Selective band gap manipulation of graphene oxide by its reduction with mild reagents. Carbon. 2015;93:967–973. doi:10.1016/j.carbon.2015.06.013
   Web of Science ®Google Scholar
• Chiu NF, Yang CD. Real-time and stepwise deoxidization processes to tune the photoluminescence properties of graphene oxide using EC-SPR spectroscopy. RSC Adv. 2018;8:11557–11565. doi:10.1039/C7RA13594G
   PubMed Web of Science ®Google Scholar
• Chiu NF, Fan SY, Yang CD, et al. Carboxyl-functionalized graphene oxide composites as SPR biosensors with enhanced sensitivity for immunoaffinity detection. Biosens Bioelectron. 2017;89:370–376. doi:10.1016/j.bios.2016.06.073
   PubMed Web of Science ®Google Scholar
• Chiu NF, Wang YH, Chen CY. Clinical application for screening down’s syndrome by using carboxylated graphene oxide-based surface plasmon resonance aptasensors. Int J Nanomedicine. 2020;15:8131–8149. doi:10.2147/IJN.S270938
   PubMed Web of Science ®Google Scholar
• Shang J, Ma L, Li J, et al. The origin of fluorescence from graphene oxide. Sci Rep. 2012;2:792. doi:10.1038/srep00792
   PubMed Web of Science ®Google Scholar
• Zheng P, Wu N. Fluorescence and sensing applications of graphene oxide and graphene quantum dots: a review. Chem Asian J. 2017;12:2343–2353. doi:10.1002/asia.201700814
   PubMed Web of Science ®Google Scholar
• Chiu NF, Huang TY, Lai HC, et al. Graphene oxide-based SPR biosensor chip for immunoassay applications. Nanoscale Res Lett. 2014;9:445. doi:10.1186/1556-276X-9-445
   PubMed Web of Science ®Google Scholar
• Rolnik DL, Wright D, Poon LC, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med. 2017;377:613–622. doi:10.1056/NEJMoa1704559
   PubMed Web of Science ®Google Scholar
• Poon LC, Shennan A, Hyett JA, et al. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: a pragmatic guide for first-trimester screening and prevention. Int J Gynaecol Obstet. 2019;145(Suppl 1):1–33. doi:10.1002/ijgo.12802
   PubMed Web of Science ®Google Scholar
• Chaemsaithong P, Sahota DS, Poon LC. First trimester preeclampsia screening and prediction. Am J Obstet Gynecol. 2022;226:S1071–97.e2.
   PubMed Web of Science ®Google Scholar
• American College of Obstetricians and Gynecologists. Gestational hypertension and preeclampsia: ACOG practice bulletin, number 222. Obstet Gynecol. 2020;135:e237–e260. doi:10.1097/AOG.0000000000003891
   PubMed Web of Science ®Google Scholar
• Chiu NF, Kuo CT, Lin TL, et al. Ultra-high sensitivity of the non-immunological affinity of graphene oxide-peptide-based surface plasmon resonance biosensors to detect human chorionic gonadotropin. Biosens Bioelectron. 2017;94:351–357. doi:10.1016/j.bios.2017.03.008
   PubMed Web of Science ®Google Scholar
• Chiu NF, Huang TY. Sensitivity and kinetic analysis of graphene oxide-based surface plasmon resonance biosensors. Sens Actuators B Chem. 2014;197:35–42. doi:10.1016/j.snb.2014.02.033
   Web of Science ®Google Scholar
• Chiu NF, Lin TL, Kuo CT. Highly sensitive carboxyl-graphene oxide-based surface plasmon resonance immunosensor for the detection of lung cancer for cytokeratin 19 biomarker in human plasma. Sens Actuators B Chem. 2018;265:264–272. doi:10.1016/j.snb.2018.03.070
   Web of Science ®Google Scholar
• Kleinrouweler CE, Cheong-See FM, Collins GS, et al. Prognostic models in obstetrics: available, but far from applicable. Am J Obstet Gynecol. 2016;214:79–90.e36. doi:10.1016/j.ajog.2015.06.013
   PubMed Web of Science ®Google Scholar
• Wu P, van den Berg C, Alfirevic Z, et al. Early pregnancy biomarkers in pre-eclampsia: a systematic review and meta-analysis. Int J Mol Sci. 2015;16:23035–23056. doi:10.3390/ijms160923035
   PubMed Web of Science ®Google Scholar
• Zakiyah N, Postma MJ, Baker PN, et al. Pre-eclampsia diagnosis and treatment options: a review of published economic assessments. Pharmacoeconomics. 2015;33:1069–1082. doi:10.1007/s40273-015-0291-x
   PubMed Web of Science ®Google Scholar
• Audibert F, Boucoiran I, An N, et al. Screening for preeclampsia using first-trimester serum markers and uterine artery Doppler in nulliparous women. Am J Obstet Gynecol. 2010;203:383.e1–8. doi:10.1016/j.ajog.2010.06.014
   PubMed Web of Science ®Google Scholar
• Pihl K, Sørensen S, Stener Jørgensen F. Prediction of preeclampsia in nulliparous women according to first trimester maternal factors and serum markers. Fetal Diagn Ther. 2020;47:277–283. doi:10.1159/000503229
   PubMed Web of Science ®Google Scholar
• van Esch JJA, van Heijst AF, de Haan AFJ, et al. Early-onset preeclampsia is associated with perinatal mortality and severe neonatal morbidity. J Matern Fetal Neonatal Med. 2017;30:2789–2794. doi:10.1080/14767058.2016.1263295
   PubMed Web of Science ®Google Scholar